MAP2K7 and plasma cell myeloma: In multiple myeloma (MM), CYT387 prevents interleukin-6 (IL-6)-induced phosphorylation of STAT3 and significantly reduces IL-6 and insulin-like growth factor-1 induced AKT phosphorylation and downstream MEK/ERK pathways, where ERK denotes the extracellular receptor kinase, while MEK denotes mitogen-activated protein kinase (Monaghan et al., 2011).